PAUL E. FENSTER, M.D.; J. ROBERT POWELL, Pharm. D.; PENELOPE E. GRAVES, Sc.D.; KENNETH A. CONRAD, M.D.; W. DAVID HAGER, M.D.; STEVEN GOLDMAN, M.D.; FRANK I. MARCUS, M.D.
The effect of quinidine on digitoxin single-dose pharmacokinetics was evaluated in five healthy adults. Blood was collected for 3 weeks, and a complete urine collection was obtained for 4 days, after a single intravenous dose of digitoxin. The protocol was conducted once while each subject was taking oral quinidine, for 3 weeks, and then repeated 10 days after discontinuing quinidine treatment. Quinidine induced the following changes in digitoxin pharmacokinetics: Elimination half-life was prolonged from 174 ± 25 to 261 ± 58 hours (p < 0.02); total body clearance decreased from 1.54 ± 0.40 to 1.09 ± 0.31 mL/h · kg (p < 0.05); renal clearance decreased from 0.65 ± 0.07 to 0.46 ± 0.17 mL/h kg (p < 0.05). Digitoxin volume of distribution and protein binding were unaltered by quinidine. Quinidine caused a rise in serum digitoxin levels. Digitoxin total body clearance was decreased by quinidine to an extent comparable to that reported for digoxin; however, the mechanism of the interaction with the two digitalis glycosides may, in part, be different.
FENSTER PE, POWELL JR, GRAVES PE, CONRAD KA, HAGER WD, GOLDMAN S, et al. Digitoxin-Quinidine Interaction: Pharmacokinetic Evaluation. Ann Intern Med. ;93:698–701. doi: 10.7326/0003-4819-93-5-698
Download citation file:
Published: Ann Intern Med. 1980;93(5):698-701.
Cardiology, Rhythm Disorders and Devices.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use